CLL Patient Exam in the Era of Targeted Therapies: Workup, Prognosis, Treatment, and Monitoring

Access Activity

Overview / Abstract:

The rapid evolution of treatment advances in chronic lymphocytic leukemia (CLL) make treatment a complex and challenging proposition. Though several randomized, controlled trials on the use of novel targeted biologic agents in CLL have been conducted, there are limited published, randomized data providing definitive guidance on treatment selection (including drug combinations and sequencing therapy), duration of treatment, management of treatment-related toxicities, and disease outcomes across different lines of therapy.

This activity has been developed to help clinicians involved in the management of patients with CLL effectively apply the newest available tailored treatments while considering such clinical features of CLL as

The implications of serum, molecular, and cytogenetic biomarkers on patient prognosis
The differences between the currently available and emerging therapeutic agents in terms of their mechanisms of action, response depth and duration, and toxicity profiles
The most current treatment advances for CLL, as well as the latest available data from ongoing clinical studies

Expiration

Mar 30, 2021

Discipline(s)

Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME

Format

Online

Credits / Hours

Albert Einstein College of Medicine-Montefiore Medical Center designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM.

Accreditation

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and RedMedEd. Albert Einstein College of Medicine-Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Presenters / Authors / Faculty

Anthony Mato, MD, MSCE—Program Chair
Associate Attending
Director, Chronic Lymphocytic Leukemia Program
Memorial Sloan Kettering Cancer Center
New York, New York

John M. Pagel, MD, PhD
Chief of Hematologic Malignancies
Director of Stem Cell Transplantation
Swedish Cancer Institute
Seattle, Washington

Chaitra S. Ujjani, MD
Clinical Associate Professor of Medicine
Division of Medical Oncology
Seattle Cancer Care Alliance
Fred Hutchinson Cancer Research Center
Seattle, Washington

Activity Specialities / Related Topics

Oncology / Cancer / Radiation Therapy, Internal Medicine, Hematology

Sponsors / Supporters / Grant Providers

This activity is supported by educational grants from AbbVie; Pharmacyclics LLC, an AbbVie Company; and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Keywords / Search Terms

Virtual, Interactive, CME, Free, RedMedEd, Patient case, MCL, CLL, Non Hodgkin lymphoma, B cell lymphoma, Mantle cell lymphoma, Chronic lymphocytic leukemia, Oncology, Hematology, BTK, Bruton tyrosine kinase, Diagnosis, Prognosis, Treatment options, Immunotherapy, Targeted therapy, Oncologist, Hematologist, Advances, Treatment, Cancer, Chemoimmunotherapy, Small lymphocytic lymphoma, Guidelines, Recommendations, Biologic

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map